To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

NCT03514901 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Metastatic
BRAF V600 Mutation

Interventions

OTHER: Experimental combination beyond Focal Progression
DRUG: Pembrolizumab or Nivolumab

Sponsor

Intergruppo Melanoma Italiano